What does HAYA Therapeutics do?
HAYA Therapeutics is a biotechnology company that pioneers precision RNA-guided regulatory genome targeting therapeutics. The company focuses on reprogramming disease-driving cell states for a broad range of conditions, including heart failure, cardiovascular, metabolic diseases, and cancer.
How much did they raise?
The company raised $65M in a Series A round led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company, ATHOS, +ND Capital, Alexandria Venture Investments, LifeLink Ventures, and several existing investors.
What are their plans for the money?
HAYA Therapeutics plans to use the funds to accelerate the clinical development of its lead candidate, HTX-001, for heart failure and to expand its RNA-guided regulatory genome pipeline. This initiative aims to enhance precision treatment options across multiple disease areas.
What have they achieved so far?
The company has already made significant strides by developing its innovative platform for targeting long non-coding RNAs, and it recently announced a major collaboration with Eli Lilly for exploring RNA-based drug targets for obesity and metabolic disorders.
